secwatch.observer — SEC 8-K summary
======================================

Issuer:     Incannex Healthcare Inc. (IXHL)
CIK:        0001873875
Form:       8-K
Filed at:   2025-07-30T23:59:59+00:00
Accession:  0001213900-25-068954
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Incannex reports positive Phase 2 results for IHL-42X in obstructive sleep apnea; AHI reduced up to 83%
--------------------------------------------------------------------------------

- IHL-42X reduced AHI up to 83% (high-dose) and 79% (low-dose) from baseline; 41.2% of high-dose patients achieved >30% reduction.
- Statistically significant improvements in PGI-C sleep related impairment, fatigue, ODI, and patient-reported outcomes (FOSQ-10, ESS, PROMIS).
- No serious adverse events reported; treatment-emergent adverse effects infrequent, mostly mild/moderate.
- Preparing End-of-Phase 2 meeting with FDA; advancing toward commercial readiness and Phase 3 development.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1873875/000121390025068954/0001213900-25-068954-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1873875/000121390025068954/ea0250564-8k_incannex.htm
  HTML page:      https://secwatch.observer/filing/0001213900-25-068954

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer